Abu Dhabi Set to Host AIM Congress 2025, Featuring Over 25,000 Participants From 180 Countries
4.9.2024 17:14:00 EEST | Business Wire | Press release
AIM Congress, the world’s premier investment platform, is set to convene in Abu Dhabi from April 7-9, 2025, under the theme “Mapping the Future of Global Investment: The New Wave of a Globalized Investment Landscape- Towards a New Balanced World Structure”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904975010/en/
HE Dr. Thani Al Zeyoudi - UAE Minister of State for Foreign Trade and President of AIM Congress (Photo: AETOSWire)
AIM 2025 will bring together industry leaders, government officials, policymakers, senior regional and international investors, as well as prominent international companies and organizations from various sectors. It will explore the latest trends, developments and opportunities shaping the global investment landscape, focusing on addressing current and future challenges and mobilizing efforts to forge innovative solutions, with the goal of fostering a prosperous and sustainable global economy.
HE Dr.Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade and President of AIM Congress, emphasized the significance of this gathering, stating, “AIM Congress 2025 is an opportunity to reaffirm the UAE’s unwavering commitment to leading global efforts in addressing the pressing economic challenges of our time. As the world navigates profound economic shifts, AIM will provide a crucial platform for the international community to come together, devise innovative investment strategies, and build a framework that ensures sustainable and inclusive growth for all.”
To accommodate the increased number of events, activities and exhibitors, the exhibition area will be doubled to over 30,000 m2. The event will host more than 25,000 distinguished participants from 180 countries, with over 1,000 speakers expected to engage in more than 350 panel discussions. To register your interest, kindly visit: www.aimcongress.com.
AIM Congress 2025 will feature events, forums, dialogue sessions, workshops, high-level meetings, the AIM Investment Awards and Exhibition, a startups competition, and showcases of country-specific investment opportunities. With two additional portfolios, AIM 2025 will tackle eight key portfolios, including Foreign Direct Investment (FDI), Global Trade, Startups & Unicorns, Future Cities, Future Finance, Global Manufacturing, Digital Economy, and Entrepreneurs.
Dawood Al Shezawi, Chairman of the Organizing Committee of AIM Congress, emphasized the event's ongoing success and increasing participation, noting that the Organising Committee is dedicated to organizing a bigger and more impactful edition to further shape a more prosperous and inclusive global economy.
For more information, click here
Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904975010/en/
Contacts
Shereen al Musalami
shereen.almusallami@aimcongress.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom